Login to Your Account



Other News To Note


Monday, May 21, 2012
• Emergent BioSolutions Inc., of Rockville, Md., said the FDA approved its supplemental biologics license application to change the administration schedule of BioThrax (anthrax vaccine adsorbed) to a three-dose primary series of intramuscular injections at zero, one month and six months.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription